Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$15.95 USD
+0.19 (1.21%)
Updated May 31, 2024 04:00 PM ET
After-Market: $15.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVDL 15.95 +0.19(1.21%)
Will AVDL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AVDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVDL
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
Here's Why You Should Invest in Avadel (AVDL) Stock Now
AVDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?
How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%
Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick
Other News for AVDL
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
Avadel Pharmaceuticals shares new data on LUMRYZ
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Avadel Pharmaceuticals appoints Amin to board of directors